Claims
- 1. A compound of the formula ##STR17## or a physiologically acceptable salt or solvate thereof wherein X represents a C.sub.1-6 alkylene group,
- Y represents a C.sub.1-6 alkylene group, with the proviso that the sum total of carbon atoms in the chains X and Y is not more than 10,
- and Het represents a pyrimidinyl group, optionally substituted by one or two groups selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy,hydroxy,halogen, --NR.sup.3 R.sup.4 and --COR.sup.8, wherein R.sup.3 and R.sup.4 each represent a hydrogen atom or a C.sub.1-4 alkyl group or --NR.sup.3 R.sup.4 forms a pyrrolidino, piperidino, hexamethyleneimino, piperazino, N-methylpiperazino, morpholino, homomorpholino or thiomorpholino group; and R.sup.8 represents hydrogen, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4.
- 2. A compound according to claim 1 wherein X represents --(CH.sub.2).sub.3 --or--(CH.sub.2).sub.4 --.
- 3. A compound according to claim 2 wherein X represents --(CH.sub.2).sub.4 --.
- 4. A compound according to claim 1 wherein Y represents a C.sub.2-5 alkylene group.
- 5. A compound according to claim 1 wherein said compound comprises 4-amino-3,5-dichloro-.alpha.-[[[6-[-(2-pyrimidinyl)butoxy]hexyl]amino]methyl]benzenemethanol or a physiologically acceptable salt or solvate thereof.
- 6. A pharmaceutical composition for therapy or prophylaxis of a disease associated with reversible airways obstruction which comprises an effective amount to alleviate said disease of at least one compound as defined in claim 1 or a physiologically acceptable salt or solvate thereof, together with a physiologically acceptable carrier or excipient.
- 7. A pharmaceutical composition according to claim 6, wherein the disease associated with reversible airways obstruction is asthma or chronic bronchitis.
- 8. A pharmaceutical composition for the treatment of an inflammatory or allergic skin disease which comprises an effective amount to alleviate said condition of at least one compound as defined in claim 1 or a physiologically acceptable salt or solvate thereof, together with a physiologically acceptable carrier or excipient.
- 9. A method of therapy or prophylaxis of a disease associated with reversible airways obstruction in a patient, which comprises administering to said patient an effective amount to alleviate said disease of at least one compound as defined in claim 1 or a physiologically acceptable salt or solvate thereof.
- 10. A method according to claim 9, wherein the disease associated with reversible airways obstruction is asthma or chronic bronchitis.
- 11. A method of treating a patient suffering from an inflammatory or allergic skin disease which method comprises administering to said patient an effective amount to alleviate said condition of at least one compound as defined in claim 1 or a physiologically acceptable salt or solvate thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8718939 |
Aug 1987 |
GBX |
|
Parent Case Info
This is a divisional of co-pending application Ser. No. 07/230,358 filed Aug. 10, 1988, now U.S. Pat. No. 4,996,218.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4438128 |
Wiedemann et al. |
Mar 1984 |
|
4721717 |
Friebe et al. |
Jan 1988 |
|
4937251 |
Lunts |
Jun 1990 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
303464 |
Aug 1988 |
EPX |
1178191 |
Jan 1970 |
GBX |
2182658 |
Oct 1986 |
GBX |
Non-Patent Literature Citations (3)
Entry |
Champion, British Medical Journal, 4 (1973) 730-732. |
Kennes et al., Clinical Allergy, 7 (1977) 35-39. |
Das et al., British Journal of Dermatology 99 (1978) 197-200. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
230358 |
Aug 1988 |
|